Kailera Therapeutics completes IPO at $500 million, raising capital for Phase 3 execution and commercialization

Kailera Therapeutics

Kailera Therapeutics priced its IPO at $14–$16 per share and raised $500 million, listing on Nasdaq under ticker KLRA. Proceeds fund Phase 3 trial execution, manufacturing capacity for ribupatide, and development of the oral formulation.

• IPO priced in the week of April 13, 2026, with underwriters J.P. Morgan, Jefferies, Leerink Partners, and others.
• Existing shareholders committed $225 million (45% of the deal) as an anchor.
• Public markets validated the dual GLP-1/GIP platform as differentiated in the obesity space.